Literature DB >> 18429969

Pharmacogenetics of aspirin resistance: a comprehensive systematic review.

Timothy Goodman1, Albert Ferro, Pankaj Sharma.   

Abstract

AIMS: The aim was to perform a systematic review of all candidate gene association studies in aspirin resistance.
METHODS: Electronic databases were searched up until 1 December 2007 for all studies investigating any candidate gene for aspirin resistance in humans. Aspirin resistance was required to have been measured by a standardized laboratory technique to be included in the analysis.
RESULTS: Within 31 studies, 50 polymorphisms in 11 genes were investigated in 2834 subjects. The PlA1/A2 polymorphism in the GPIIIa platelet receptor was the most frequently investigated, with 19 studies in 1389 subjects. The PlA1/A2 variant was significantly associated with aspirin resistance when measured in healthy subjects [odds ratio (OR) 2.36, 95% confidence interval (CI) 1.24, 4.49; P = 0.009]. Combining genetic data from all studies (comprising both healthy subjects and those with cardiovascular disease) reduced the observed effect size (OR 1.14, 95% CI 0.84, 1.54; P = 0.40). Moreover, the observed effect of PlA1/A2 genotype varied depending on the methodology used for determining aspirin sensitivity/resistance. No significant association was found with aspirin resistance in four other investigated polymorphisms in the COX-1, GPla, P2Y1 or P2Y12 genes.
CONCLUSIONS: Our data support a genetic association between the PlA1/A2 molecular variant and aspirin resistance in healthy subjects, with the effect diminishing in the presence of cardiovascular disease. The laboratory methodology used influences the detection of aspirin resistance. However, as heterogeneity was significant and our results are based on a limited number of studies, further studies are required to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18429969      PMCID: PMC2492913          DOI: 10.1111/j.1365-2125.2008.03183.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  59 in total

1.  Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers.

Authors:  P Fontana; S Nolli; G Reber; P de Moerloose
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis.

Authors:  Burak Pamukcu; Huseyin Oflaz; Yilmaz Nisanci
Journal:  Am Heart J       Date:  2005-04       Impact factor: 4.749

Review 3.  Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.

Authors:  C P M Hayward; P Harrison; M Cattaneo; T L Ortel; A K Rao
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 4.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

5.  Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.

Authors:  Roger Kranzhofer; Johannes Ruef
Journal:  Platelets       Date:  2006-05       Impact factor: 3.862

6.  Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.

Authors:  Jerzy Dropinski; Jacek Musial; Marek Sanak; Wojciech Wegrzyn; Rafal Nizankowski; Andrew Szczeklik
Journal:  Thromb Res       Date:  2006-05-03       Impact factor: 3.944

Review 7.  Current options in platelet function testing.

Authors:  Alan D Michelson; Andrew L Frelinger; Mark I Furman
Journal:  Am J Cardiol       Date:  2006-09-29       Impact factor: 2.778

8.  P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Authors:  Anneke Bierend; Thomas Rau; Renke Maas; Edzard Schwedhelm; Rainer H Böger
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

9.  Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.

Authors:  Aino Lepäntalo; Jussi Mikkelsson; Julio C Reséndiz; Leena Viiri; Janne T Backman; Esko Kankuri; Pekka J Karhunen; Riitta Lassila
Journal:  Thromb Haemost       Date:  2006-02       Impact factor: 5.249

Review 10.  The genetics of aspirin resistance.

Authors:  Timothy Goodman; Pankaj Sharma; Albert Ferro
Journal:  Int J Clin Pract       Date:  2007-03-28       Impact factor: 2.503

View more
  45 in total

1.  Mapping genes that predict treatment outcome in admixed populations.

Authors:  T M Baye; R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

2.  Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation.

Authors:  Jefferson C Frisbee; Adam G Goodwill; Phoebe A Stapleton; Stephanie J Frisbee; Alexandre C d'Audiffret
Journal:  Physiol Genomics       Date:  2010-06-08       Impact factor: 3.107

3.  Looking back: editors' pick of 2008.

Authors:  Y K Loke; A Somogyi; L D Lewis; M Schachter; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 4.  The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.

Authors:  Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

Review 5.  Genomic view of factors leading to plaque instability.

Authors:  Sonny Dandona; Robert Roberts
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

Review 6.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

Review 7.  Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications.

Authors:  Eugenia Yiannakopoulou
Journal:  Eur J Clin Pharmacol       Date:  2013-02-24       Impact factor: 2.953

8.  Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin.

Authors:  A Dudley; J Thomason; S Fritz; J Grady; J Stokes; R Wills; L Pinchuk; A Mackin; K Lunsford
Journal:  J Vet Intern Med       Date:  2012-12-26       Impact factor: 3.333

9.  Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.

Authors:  Zhigang Zhao; Xingang Li; Shusen Sun; Shenghui Mei; Ning Ma; Zhongrong Miao; Ming Zhao; Shiqi Peng
Journal:  Eur J Clin Pharmacol       Date:  2016-07-23       Impact factor: 2.953

10.  Aspirin resistance.

Authors:  Khaled Mansour; Ali T Taher; Khaled M Musallam; Samir Alam
Journal:  Adv Hematol       Date:  2009-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.